21 results about "Mg citrate" patented technology

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

A micronutrient composition comprises of several combinations of individual ingredients in forming Mix 11, G12, G13 and core mix formulation. Core mix contains magnesium citrate, alpha-Ketoglutaric acid, L-Citrulline and Taurine. The Mix 11, G12 and G13 contains Magnesium Citrate, Alpha-Ketoglutaric Acid, Niacinamide, L-Glutamine, L-Citrulline, Sodium Pyruvate, Succinic acid, Vitamin B complex, Taurine, L-Cysteine, L-Methionine, L-Ascorbic Acid, Coenzyme Q10 or combination thereof. A method of administering and treating a specific disease which is due to one of an oxidative stress, impaired mitobiogenesis and ATP production in a mammal is disclosed.

The invention discloses a formula and a processing method for ecological culture of crustacean aquatic products, and the formula comprises the following medicines by weight: glycine / methionine chelated trace elements: by taking glycine as an example, not less than 13% of magnesium citrate, 9-20 g of magnesium citrate, not less than 21% of zinc glycinate, 5-9.5 g of zinc glycinate, not less than 15% of manganese glycinate, 3.5-6.5 g of manganese glycinate, not less than 15% of copper glycinate, and 1-2.5 g of copper glycinate; 6-11g of ferrous glycinate with the concentration of more than or equal to 17%; the selenium content of the yeast is 2,000 PPM, and is 1-1.5 g; per kilogram of the vitamin compound comprises 550000-8000000 IU of vitamin A, 150000-45000000 IU of vitamin D3, more than or equal to 3500 milligrams of vitamin E, more than or equal to 1200 milligrams of vitamin K3, more than or equal to 800 milligrams of vitamin B1, more than or equal to 5000 milligrams of vitamin B2, more than or equal to 800 milligrams of vitamin B6, more than or equal to 2000 micrograms of vitamin B12 and more than or equal to 15000 milligrams of vitamin C; the invention relates to the technical field of aquaculture, the formula realizes the virtuous cycle of efficient absorption, sedimentation, slow release, decomposition and supply of trace elements through artificial and natural synergistic nutrition chain design, and achieves the ecological breeding target of'zero emission 'of nutrient substances and'zero addition' of chemical agents.

The invention belongs to the technical field of solid beverages, and discloses a solid beverage containing magnesium and potassium and a preparation method thereof, the solid beverage comprises magnesium salt and potassium salt, and the mass ratio of K < + > to Mg < 2 + > is (2-5): 1; the potassium salt is potassium citrate; the magnesium salt is selected from at least one of magnesium oxide, magnesium gluconate, magnesium glycinate or magnesium citrate. Sylvite and magnesium salt are sieved and then added into purified water to be dissolved, and then spray drying is carried out; and carrying out subsequent packaging on the dried solid particles. The mass ratio of the main components K < + > to Mg < 2 + > of the magnesium-potassium solid beverage is (2: 1)-(5: 1), the two components in the ratio have a synergistic effect, the effect of improving sleep and constipation can be enhanced, and the effect is remarkably reduced when the ratio is not within the range.

The application relates to a low-temperature synthesis-based magnesia-alumina spinel corundum powder and a preparation method thereof. The technical scheme is as follows: taking magnesium citrate and magnesium sulfate heptahydrate as magnesium sources, tabular corundum micro powder as an alumina source, and magnesium chloride hexahydrate as a molten salt medium. The magnesium citrate and the magnesium sulfate heptahydrate are mixed and then added into deionized water to obtain solution A after stirring; the tabular corundum micro powder is added into the solution A to obtain mixture B after stirring and drying; the magnesium chloride hexahydrate is mixed with the mixture B to obtain mixture C after stirring. The mixture C is pressed into a shape, heated to 1000-1300 DEG C under the condition of a flowing protective atmosphere in a high-temperature tube furnace, kept warm, and cooled with the furnace; the mixture C is broken, washed with deionized water, washed with isopropyl alcohol again, and dried to obtain the low-temperature synthesis-based magnesia-alumina spinel corundum powder. The low-temperature synthesis-based magnesia-alumina spinel corundum powder prepared by the application has a complete coating structure, high bonding strength, excellent erosion resistance and high purity.

Provided are an application of a citrate metal salt in endodontic treatment, and a formulation obtained by preparation; said citrate metal salt is used for removing a tarnished layer, and the citrate metal salt is lithium citrate, sodium citrate, potassium citrate, or magnesium citrate. The citrate metal salt is co-formulated with a citrate metal salt-compatible single-chain cationic antimicrobial agent, achieving results that are currently achieved only by alternating rinsing with EDTA-containing and sodium hypochlorite preparations in endodontic treatment.

The present application discloses a kind of magnesium citrate sustained-release pellets and a preparation method thereof, the magnesium citrate sustained-release pellets can control the release degree of magnesium in the stomach, and improve the bioavailability.Single magnesium citrate sustained-release pellets are developed, and compound magnesium citrate and magnesium oxide sustained-release pellets are a combination of multiple units, have the function of controlling release in the stomach, are not affected by food rhythm, are suitable for old people and children, improve compliance, overcome the adverse reactions caused by granules and tablets.The magnesium citrate and magnesium oxide pellet dosage form has not been seen at home and abroad, and is the first at home and abroad.

The invention belongs to the field of citrate production, and particularly relates to a preparation method of magnesium hydrogen citrate, which comprises the following steps: reacting a citric acid solution with magnesium citrate under certain conditions to generate magnesium hydrogen citrate, and then centrifuging and drying to obtain a finished product of magnesium hydrogen citrate. The provided preparation method is simple in process and low in cost and energy consumption, the prepared magnesium hydrogen citrate is high in solubility, the solubility is 19-20 g / L at the normal temperature, the magnesium content is appropriate and is 9-10 wt%, the magnesium hydrogen citrate is high in safety, and the magnesium hydrogen citrate can be easily absorbed and utilized by a human body and can be applied to electuary, tablets, oral liquid capsules, injections, beverages and food.

The invention relates to an agent for application to skin areas of a human for increasing the power of muscles of the human under the skin areas in the event of anaerobic stress, in particular for reducing a lactate concentration in muscles under the skin areas. The agent expediently has a beta-alanine content of between 5.00 vol.% and 20.00 vol.% and a water content of between 20.00 vol.% and 95.00 vol.%. Overall, the claimed content of beta-alanine leads to a low-side-effect increase in power of those muscles that lie below skin areas treated with an agent according to the invention. In one embodiment of the invention, the agent additionally comprises water-soluble magnesium salt, wherein a content of the water-soluble magnesium salt is between 3.00 vol.% and 6.00 vol.%, and wherein the water-soluble magnesium salt is selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium acetate, magnesium citrate, magnesium glycinate and magnesium gluconate.

This invention discloses a method for preparing magnesium citrate. The method includes: first, preparing citric acid solution and magnesium salt solution of specific concentrations, and introducing them separately into specific microfluidic chip channels; then, precisely controlling the flow rate of the solutions in the channels, and the temperature and pressure of the reaction zone, to promote thorough mixing and efficient reaction of the two solutions in the region, thereby constructing a stable pure liquid reaction system. This invention, through precise control, rigorously manages the reaction process and mixing degree, effectively avoiding drawbacks such as uneven product quality, inconsistent crystal morphology and size caused by premature crystallization. The prepared magnesium citrate exhibits many superior properties: its magnesium content is close to the theoretical value of 16.2%; its purity is over 95%; the reaction time is significantly shortened; it possesses excellent reproducibility and reduces the occurrence of side reactions, providing a novel and efficient approach for the preparation of magnesium citrate.

A thermogenic composition prevents the adverse effects of cold exposure and / or mitigates hypothermia. Epinephrine, atropine sulfate, phenylephrine hydrochloride, L-carnitine, vitamin B12, magnesium sulfate, and saline solution are homogeneously mixed to form an injectable formulation for the thermogenic composition. Capsaicinoids, capsinoids, ginger extract, L-citrulline, grains of paradise extract, taurine, caffeine anhydrous, L-theanine, green tea extract, black pepper extract, potassium citrate, sodium citrate, and magnesium citrate anhydrous are heterogeneously mixed to form a capsulated formulation for the thermogenic composition.

The invention belongs to the technical field of preparation of barium compounds, and relates to a preparation method of suspended barium sulfate. According to the method, magnesium citrate is introduced as a crystal form regulating agent in the initial stage of a barium sulfate precipitation reaction, and the flaky or fusiform barium sulfate with the high specific surface area is obtained by synergistically regulating crystal growth kinetics through magnesium ions and citrate ions. The obtained product has excellent suspension stability, high crystal purity and good redispersibility without surface modification, and is suitable for aqueous phase and organic medium systems.

The present patent of invention relates to a novel dietary supplement, preferably produced in the form of tablets, intended for the relief of cramps and muscle pain, as well as for reducing fatigue and physical tiredness, enhancing physical performance and promoting a sense of well-being. The composition of each tablet (360 mg) includes: 1 mg of vitamin B1; 1.3 mg of vitamin B2; 15 mg of vitamin B3; 2.5 mg of vitamin B5; 39 mg of vitamin B6; 100 mg of ubiquinone; 22 mcg (micrograms) of biotin; 200 mg of MCTs (total fats); 50 mg of magnesium malate; 50 mg of magnesium citrate; and 0.8 mg of chelated manganese.

The utility model relates to the technical field of chemical equipment, and disclose a kind of ion exchange type magnesium citrate reaction kettle, including reaction kettle assembly, and the middle part of reaction kettle assembly is fastened and connected with stirring assembly, and stirring assembly includes motor and motor output shaft end fastening connection has rotating roller, rotating roller circumferential surface is fixedly connected with helical blade, and rectangular blade is fixedly connected between helical blade gap, and kettle cover assembly is placed on the upper surface of reaction kettle assembly, and the upper surface of kettle cover assembly is evenly fixedly connected with feeding assembly. The ion exchange type magnesium citrate reaction kettle, by the stirring assembly and feeding assembly being set, solve the ion exchange type magnesium citrate reaction kettle of existing, the single of stirring structure is relatively, to lead to the problem of low reaction efficiency, ion exchange is not sufficient;Or the connecting portion between feeding structure and feeding pipe is generally sealed by sealing washer, but sealing washer is difficult to quickly and accurately position, to lead to the risk of leakage still exists in connecting portion.

The invention provides a dairy product substitute beverage. The invention relates to a dairy product composition comprising a dairy product replacement component, one or more high-potency sweeteners, and one or more organic acid salts selected from the group consisting of sodium gluconate, sodium citrate, sodium lactate, potassium gluconate, potassium citrate, potassium lactate, calcium gluconate, calcium citrate, calcium lactate, calcium lactate gluconate, magnesium gluconate, magnesium citrate, magnesium lactate, magnesium lactate gluconate and anhydrous and hydrate forms thereof.

The application belongs to the technical field of barium compound preparation, and relates to a preparation method of suspended barium sulfate. In the method, magnesium citrate is introduced as a crystal form regulator in the initial stage of the barium sulfate precipitation reaction, and the crystal growth kinetics is cooperatively regulated by magnesium ions and citrate ions, so that flaky or fusiform high-specific-surface-area barium sulfate is obtained. The obtained product has excellent suspension stability, high crystalline purity and good redispersibility without surface modification, and is suitable for water phase and organic medium systems.

A dairy beverage is provided, the present invention relates to a dairy composition comprising one or more dairy components, one or more high potency sweeteners, and one or more organic acid salts selected from the group consisting of sodium gluconate, sodium citrate, sodium lactate, potassium gluconate, potassium citrate, potassium lactate, calcium gluconate, calcium citrate, calcium lactate, calcium lactate gluconate, magnesium gluconate, magnesium citrate, magnesium lactate, magnesium lactate gluconate and anhydrous and hydrate forms thereof.

Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.

An anti-anxiety composition includes 2 grams of Beta Alanine; 0.75 grams of agmatine sulfate; 0.75 grams of taurine; 0.75 grams of magnesium citrate; and 100 mg of l-theanine. A method for decreasing anxiety in a subject includes administering to the subject a drinkable liquid that includes 0.25-2 grams of Beta Alanine.

The invention relates to a solid, analgesic dosage form for oral administration with abuse deterrent properties, said dosage form comprising: (a) one or more active ingredients having potential for abuse selected from the group consisting of Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, hydrocodone bitartrate, Hydromorphone, Levorphanol tartrate, Meperidine hydrochloride, Methadone, Morphine, Normethadone, Opium, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol, TEV-90105, ELI-202, or pharmaceutically acceptable salts and solvates thereof; (b) magnesium salt selected from the group consisting of consisting of Magnesium acetate, Magnesium benzoate, Magnesium bromate, Magnesium bromide, Magnesium carbonate, Magnesium chlorate, Magnesium chloride, Magnesium chromate, Magnesium citrate, Magnesium fluoride, Magnesium fluorosilicate, Magnesium formate, Magnesium glycinate, magnesium hydroaspartate, Magnesium hydroxide, Magnesium iodate, Magnesium iodide, Magnesium lactate, Magnesium L-threonate, Magnesium Malate, Magnesium molybdate, Magnesium nitrate, Magnesium oxalate, Magnesium oxide, Magnesium perchlorate, Magnesium phosphate, Magnesium selenite, Magnesium sulfate, Magnesium sulfate heptahydrate, Magnesium sulfite, Magnesium thiosulfate or a combination thereof, c) piperine.

The invention provides a magnesium composition with a dysmenorrhea relieving effect as well as a preparation method and application thereof, and relates to the technical field of medicines. The magnesium composition with the dysmenorrhea relieving effect is prepared from the following raw materials: chelated magnesium and an antioxidant, the chelated magnesium is selected from at least one of magnesium threonate, magnesium citrate, magnesium malate, magnesium taurine and magnesium lysine. According to the magnesium composition prepared by the invention, the specific chelated magnesium and the antioxidant are used as raw materials and interact with each other, so that the curative effect is remarkable; the technical defect that in the prior art, a method for relieving dysmenorrhea is poor in effect or has untoward effects is overcome.